Gene:
APP
amyloid beta (A4) precursor protein

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no clinical annotations for this gene. To report clinical variants, click here.

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

Overview

Alternate Names:  A4 amyloid protein; Amyloid beta (A4) precursor protein; OTTHUMP00000096096; PN-II; alzheimer disease amyloid protein; amyloid beta (A4) precursor protein (peptidase nexin-II, Alzheimer disease); amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease); amyloid beta A4 protein; amyloid beta-peptide; amyloid-beta protein; beta-amyloid peptide; cerebral vascular amyloid peptide; human mRNA for amyloid A4 precursor of Alzheimer's disease; peptidase nexin-II; preA4; protease nexin-II
Alternate Symbols:  AAA; ABETA; ABPP; AD1; APPI; CTFgamma; CVAP; PN2
PharmGKB Accession Id: PA24910

Details

Cytogenetic Location: chr21 : q21.3 - q21.3
GP mRNA Boundary: chr21 : 27252861 - 27543446
GP Gene Boundary: chr21 : 27249861 - 27553446
Strand: minus
Product Name: No data available
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to APP: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic counseling and testing for Alzheimer disease: Joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genetics in medicine : official journal of the American College of Medical Genetics. 2011. Goldman Jill S, et al. [Article:21577118@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD11c as a transcriptional biomarker to predict response to anti-TNF monotherapy with adalimumab in patients with rheumatoid arthritis. Clinical pharmacology and therapeutics. 2010. Stuhlmüller B, et al. [Article:20032971@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA : the journal of the American Medical Association. 2009. Mattsson Niklas, et al. [Article:19622817@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science (New York, N.Y.). 2009. Di Fede Giuseppe, et al. [Article:19286555@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Abeta-degrading enzymes in Alzheimer's disease. Brain pathology (Zurich, Switzerland). 2008. Miners James Scott, et al. [Article:18363935@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (New York, N.Y.). 2008. Rajendran Lawrence, et al. [Article:18436784@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. American journal of human genetics. 2007. Liu Fan, et al. [Article:17564960@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. Lancet neurology. 2007. Kehoe Patrick G, et al. [Article:17362841@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (New York, N.Y.). 2007. Roberson Erik D, et al. [Article:17478722@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. American journal of human genetics. 2006. Theuns Jessie, et al. [Article:16685645@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
100 years and counting: prospects for defeating Alzheimer's disease. Science (New York, N.Y.). 2006. Roberson Erik D, et al. [Article:17082448@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A century of Alzheimer's disease. Science (New York, N.Y.). 2006. Goedert Michel, et al. [Article:17082447@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (New York, N.Y.). 2006. Meyer-Luehmann Melanie, et al. [Article:16990547@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Alzheimer's disease with asymmetric parietal lobe atrophy: a case report. Journal of the neurological sciences. 1998. Kaida K, et al. [Article:9804125@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.